Jaa Roberson - Day One Chief Officer
| DAWN Stock | USD 12.92 0.08 0.62% |
Insider
Jaa Roberson is Chief Officer of Day One Biopharmaceuticals
| Address | 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
| Phone | 650 484 0899 |
| Web | https://dayonebio.com |
Day One Management Efficiency
The company has return on total asset (ROA) of (0.4267) % which means that it has lost $0.4267 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6997) %, meaning that it created substantial loss on money invested by shareholders. Day One's management efficiency ratios could be used to measure how well Day One manages its routine affairs as well as how well it operates its assets and liabilities. As of the 14th of June 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.62. At this time, Day One's Net Tangible Assets are very stable compared to the past year. As of the 14th of June 2024, Non Currrent Assets Other is likely to grow to about 263.7 K, while Total Assets are likely to drop about 239.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Christopher MD | Arcellx | 44 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Neeraj Teotia | Arcellx | 49 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Nevan JD | Rezolute | 57 | |
| Filip MD | Monte Rosa Therapeutics | 49 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| MBA MD | Eliem Therapeutics | 63 | |
| James JD | Eliem Therapeutics | 58 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Kate Aiken | Arcellx | N/A | |
| LLM JD | Rezolute | 63 | |
| Narinderjeet MS | Arcellx | 52 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| MD MBA | Rezolute | N/A | |
Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.43 |
Day One Biopharmaceu Leadership Team
Elected by the shareholders, the Day One's board of directors comprises two types of representatives: Day One inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Day. The board's role is to monitor Day One's management team and ensure that shareholders' interests are well served. Day One's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Day One's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD Chiodin, Chief Officer | ||
| Charles II, CFO COO | ||
| Jaa Roberson, Chief Officer | ||
| Elly MD, Chief Officer | ||
| MBA II, CFO COO | ||
| Adam Dubow, General Counsel | ||
| Lauren MBA, Chief Officer | ||
| Julie MBA, CoFounder Director | ||
| Jeremy MBA, President CEO | ||
| Prof MD, Chief Officer | ||
| Mike Preigh, Chief Operations |
Day Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Day One a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | 818.42 M | ||||
| Shares Outstanding | 87.39 M | ||||
| Shares Owned By Insiders | 19.71 % | ||||
| Shares Owned By Institutions | 84.95 % | ||||
| Number Of Shares Shorted | 10.66 M | ||||
| Price To Earning | 3.88 X | ||||
| Price To Book | 3.47 X | ||||
| EBITDA | (205.68 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Day Stock
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.50) | Return On Assets (0.43) | Return On Equity (0.70) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.